Sanofi-Synthélabo selects Dionex Chromeleon chromatography management system for implementation at all eight of its sites around the world
Sanofi-Synthélabo, one of the world's top twenty pharmaceutical companies, has chosen Dionex as the sole supplier of chromatography data systems for its pre-clinical development operations.
Dionex will implement its Chromeleon chromatography management system to automate approximately 200 chromatographs at eight Sanofi-Synthélabo sites in France, UK, USA, Hungary, and Italy.
Among the features that Sanofi-Synthélabo cited as key factors in the decision were the system's multi-vendor instrument support capabilities, its implementation of 21 CFR Part 11 compliance features, and the flexibility and user friendliness of the Chromeleon user interface.
Because Chromeleon fully controls a wide range of third-party instruments, it will provide Sanofi-Synthélabo with a unified software platform for harmonising operations across multiple laboratories.
Operators will be able to monitor and control diverse instruments from local or remote computers, without having to learn different user interfaces.
The software's distributed client/server architecture will make it easy to phase the rollout, and to update laboratory and IT strategies as needs change in the future.
To simplify administration, Chromeleon will be deployed on existing Oracle databases; powerful query tools in Chromeleon will let system users rapidly retrieve data on demand.
Integrated spreadsheet functions will be used to generate reports tailored to project requirements, and Sanofi-Synthélabo will use Chromeleon's security, validation, audit trail, and electronic signature capabilities to maintain electronic records in compliance with GLP, GMP, and 21 CFR Part 11. Sanofi-Synthélabo is the second largest pharmaceutical company in France, the 7th in Europe, and ranks among the 20 leading pharmaceutical companies in the world.
It employs 6000 scientific and support staff in 15 research and development centres, with a research and development budget of 1 billion euros.
The company has 50 pharmaceutical compounds in development.
